Skip to main
IMDX

Oncocyte Corp (IMDX) Stock Forecast & Price Target

Oncocyte Corp (IMDX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insight Molecular Diagnostics Inc. is positioned for substantial long-term revenue growth driven by its innovative diagnostic tests for organ transplant monitoring and cancer. The company's ongoing rebranding of its GraftAssure product line and the expansion of its addressable market, which could see a 10-20% increase through additional reimbursement for new testing indications, further support this optimistic projection. Key catalysts for growth include favorable clinical data, potential guideline changes from the National Comprehensive Cancer Network (NCCN), and accelerated revenue generation, all of which reinforce the company's strong market potential.

Bears say

Insight Molecular Diagnostics Inc. has experienced a significant decline in gross margin, decreasing from 67.6% in 2Q25 to 53.5%, despite surpassing estimates. Additionally, while operating expenses were slightly higher than anticipated, the company's cash burn remains a concern, with risks including slower physician adoption, reimbursement uncertainties, and potential dilution from equity offerings. Furthermore, the company may face limited revenue generation from its GraftAssureIQ assay until the anticipated IVD clearance for GraftAssureDx, projected for mid-2026.

Oncocyte Corp (IMDX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncocyte Corp (IMDX) Forecast

Analysts have given Oncocyte Corp (IMDX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Oncocyte Corp (IMDX) has a Strong Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncocyte Corp (IMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.